top of page

Exploring Canurta's Dual Inhibition Approach to Inflammation

Polyphenols have been extensively studied for their beneficial properties, including their antioxidant, anti-inflammatory, and anticancer effects. In fact, over 7,000 publications on polyphenol research were produced globally between 2000 to 2016. For Canurta specifically, the discovery and understanding of cannflavins mark significant milestones for our research and development.

An Overview of Flavonoids and Important Discoveries

The identification of these compounds was made possible by the isolation of rutin in 1930, and the subsequent recognition of over 4,000 flavonoids — a family of polyphenolic compounds. Then in the 1980s, Barrett and colleagues conducted studies which revealed that Cannflavin A and B exhibit anti-inflammatory properties that are 30 times more potent than aspirin without any associated toxicity.

In 2014, Werz and his team further validated these findings by demonstrating that these compounds act as dual inhibitors of mPGES-1 and 5-LO enzymes. These enzymes play a crucial role in the biosynthesis of pro-inflammatory mediators, presenting a potential breakthrough in treating inflammatory diseases.

mPGES-1 Enzyme's Role in Inflammation

Inflammatory components are a common feature of many diseases, and mPGES-1 is critical in this process. Due to their selectivity and safety profile, drugs that target this enzyme are considered safer than NSAIDs/COXIBs. Dual inhibition, as seen with cannflavins, could be a promising approach for more effective and comprehensive inflammation management.

Combining cannflavins into anti-inflammatory treatments, as demonstrated by Canurta's CNR-100 therapeutics, provides an alternative solution to standard therapies that target only one inflammatory pathway.

Overcoming Commercialization Obstacles for Cannflavins

Canurta is leading the way with a mission to leverage top-notch expertise in various fields, including plant biology, metabolic biochemistry, and genetics. The goal is clear: to overcome obstacles to commercializing prenylated flavonoids, specifically cannflavins A & B.

With control over intellectual property and defensible technology, Canurta has pioneered these polyphenolic compounds' growth, extraction, and biosynthesis on a commercial scale, a significant achievement for both human and animal health industries. The offerings are varied and customized, ranging from powdered hemp polyphenol-rich ingredients to highly concentrated extracts and pure, single polyphenols of interest, embodying Canurta's commitment to innovation, effectiveness, and comprehensive health solutions.

50 views0 comments


bottom of page